Cargando…
Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data
BACKGROUND: Acute myocardial infarction (AMI), a major source of morbidity and mortality, is also associated with excess costs. Findings from previous studies were divergent regarding the effect on health care expenditure of adherence to guideline-recommended medication. However, gender-specific med...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751107/ https://www.ncbi.nlm.nih.gov/pubmed/33342431 http://dx.doi.org/10.1186/s12913-020-05946-4 |
_version_ | 1783625607195656192 |
---|---|
author | Kirsch, Florian Becker, Christian Kurz, Christoph Schwettmann, Lars Schramm, Anja |
author_facet | Kirsch, Florian Becker, Christian Kurz, Christoph Schwettmann, Lars Schramm, Anja |
author_sort | Kirsch, Florian |
collection | PubMed |
description | BACKGROUND: Acute myocardial infarction (AMI), a major source of morbidity and mortality, is also associated with excess costs. Findings from previous studies were divergent regarding the effect on health care expenditure of adherence to guideline-recommended medication. However, gender-specific medication effectiveness, correlating the effectiveness of concomitant medication and variation in adherence over time, has not yet been considered. METHODS: We aim to measure the effect of adherence on health care expenditures stratified by gender from a third-party payer’s perspective in a sample of statutory insured Disease Management Program participants over a follow-up period of 3-years. In 3627 AMI patients, the proportion of days covered (PDC) for four guideline-recommended medications was calculated. A generalized additive mixed model was used, taking into account inter-individual effects (mean PDC rate) and intra-individual effects (deviation from the mean PDC rate). RESULTS: Regarding inter-individual effects, for both sexes only anti-platelet agents had a significant negative influence indicating that higher mean PDC rates lead to higher costs. With respect to intra-individual effects, for females higher deviations from the mean PDC rate for angiotensin-converting enzyme (ACE) inhibitors, anti-platelet agents, and statins were associated with higher costs. Furthermore, for males, an increasing positive deviation from the PDC mean increases costs for β-blockers and a negative deviation decreases costs. For anti-platelet agents, an increasing deviation from the PDC-mean slightly increases costs. CONCLUSION: Positive and negative deviation from the mean PDC rate, independent of how high the mean was, usually negatively affect health care expenditures. Therefore, continuity in intake of guideline-recommended medication is important to save costs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-020-05946-4. |
format | Online Article Text |
id | pubmed-7751107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77511072020-12-22 Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data Kirsch, Florian Becker, Christian Kurz, Christoph Schwettmann, Lars Schramm, Anja BMC Health Serv Res Research Article BACKGROUND: Acute myocardial infarction (AMI), a major source of morbidity and mortality, is also associated with excess costs. Findings from previous studies were divergent regarding the effect on health care expenditure of adherence to guideline-recommended medication. However, gender-specific medication effectiveness, correlating the effectiveness of concomitant medication and variation in adherence over time, has not yet been considered. METHODS: We aim to measure the effect of adherence on health care expenditures stratified by gender from a third-party payer’s perspective in a sample of statutory insured Disease Management Program participants over a follow-up period of 3-years. In 3627 AMI patients, the proportion of days covered (PDC) for four guideline-recommended medications was calculated. A generalized additive mixed model was used, taking into account inter-individual effects (mean PDC rate) and intra-individual effects (deviation from the mean PDC rate). RESULTS: Regarding inter-individual effects, for both sexes only anti-platelet agents had a significant negative influence indicating that higher mean PDC rates lead to higher costs. With respect to intra-individual effects, for females higher deviations from the mean PDC rate for angiotensin-converting enzyme (ACE) inhibitors, anti-platelet agents, and statins were associated with higher costs. Furthermore, for males, an increasing positive deviation from the PDC mean increases costs for β-blockers and a negative deviation decreases costs. For anti-platelet agents, an increasing deviation from the PDC-mean slightly increases costs. CONCLUSION: Positive and negative deviation from the mean PDC rate, independent of how high the mean was, usually negatively affect health care expenditures. Therefore, continuity in intake of guideline-recommended medication is important to save costs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-020-05946-4. BioMed Central 2020-12-20 /pmc/articles/PMC7751107/ /pubmed/33342431 http://dx.doi.org/10.1186/s12913-020-05946-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Kirsch, Florian Becker, Christian Kurz, Christoph Schwettmann, Lars Schramm, Anja Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data |
title | Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data |
title_full | Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data |
title_fullStr | Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data |
title_full_unstemmed | Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data |
title_short | Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data |
title_sort | effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751107/ https://www.ncbi.nlm.nih.gov/pubmed/33342431 http://dx.doi.org/10.1186/s12913-020-05946-4 |
work_keys_str_mv | AT kirschflorian effectsofadherencetopharmacologicalsecondarypreventionafteracutemyocardialinfarctiononhealthcarecostsananalysisofrealworlddata AT beckerchristian effectsofadherencetopharmacologicalsecondarypreventionafteracutemyocardialinfarctiononhealthcarecostsananalysisofrealworlddata AT kurzchristoph effectsofadherencetopharmacologicalsecondarypreventionafteracutemyocardialinfarctiononhealthcarecostsananalysisofrealworlddata AT schwettmannlars effectsofadherencetopharmacologicalsecondarypreventionafteracutemyocardialinfarctiononhealthcarecostsananalysisofrealworlddata AT schrammanja effectsofadherencetopharmacologicalsecondarypreventionafteracutemyocardialinfarctiononhealthcarecostsananalysisofrealworlddata |